H.C. Wainwright lowered the firm’s price target on Voyager Therapeutics (VYGR) to $25 from $30 and keeps a Buy rating on the shares. Voyager reported strong Q3 results, ending the quarter with $229M in cash and operational runway into 2028, while remaining eligible for up to $2.4B in partner milestones, the analyst tells investors in a research note. The company also advanced its NeuroShuttle non-viral delivery technology, with upcoming preclinical and trial data presentations expected to drive potential inflection points, the firm says.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VYGR:
- Voyager Therapeutics Reports Increased Losses Amid Rising R&D Costs
- Voyager Therapeutics: Strong Financial Position and Promising Pipeline Justify Buy Rating
- Voyager Therapeutics files $400M mixed securities shelf
- Voyager Therapeutics price target lowered to $11 from $12 at Leerink
- Voyager Therapeutics reports Q3 EPS (47c), consensus (52c)